60
Participants
Start Date
July 9, 2020
Primary Completion Date
April 28, 2022
Study Completion Date
April 28, 2022
ICP-022
Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
ICP-022
Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
ICP-022
Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Placebos
Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Peking University People's Hospital, Beijing
Peking University third hospital, Beijing
Gulou Hospital Affiliated to Medical College of Nanjing University, Nanjing
The First Affiliated Hospital of Bengbu Medical College, Bengbu
Guangdong General Hospital, Guangzhou
Shenzhen People's Hospital, Shenzhen
University of Hong Kong Shenzhen Hospital, Shenzhen
First Affiliated Hospital of Zhengzhou University, Zhengzhou
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Huashan Hospital affiliated to Fudan University, Shanghai
The First Affiliated Hospital of Shanxi Medical University, Taiyuan
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY